Biblio

Export 58 results:
Tekijä [ Otsikko(Desc)] Tyyppi Vuosi
Suodattimet: First Letter Of Last Name is A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, ym.. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J [Internet]. 1997;16(13):3898 - 911. http://view.ncbi.nlm.nih.gov/pubmed/9233800PDF icon Vladimir Joukov et al., EMBO Journal 1997 (729.21 KB)
R
Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, ym.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699PDF icon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB)PDF icon Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
S
Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, ym.. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889PDF icon Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)
Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, ym.. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889PDF icon Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)
Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, ym.. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. Teoksessa Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Miami Beach, Florida; 2001. PDF icon Jussila et al., 2001 (279.47 KB)
Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, ym.. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. Teoksessa Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Miami Beach, Florida; 2001. PDF icon Jussila et al., 2001 (279.47 KB)
Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, ym.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116PDF icon Veli-Matti Leppänen et al. PNAS 2010 (1 MB)PDF icon Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB)
Leppänen V-M, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, ym.. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116PDF icon Veli-Matti Leppänen et al. PNAS 2010 (1 MB)PDF icon Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB)
Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, ym.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085PDF icon Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB)PDF icon Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, ym.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085PDF icon Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB)PDF icon Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, ym.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085PDF icon Veli-Matti Leppänen & Michael Jeltsch et al., Blood 2011 (1.17 MB)PDF icon Veli-Matti Leppänen & Michael Jeltsch et al. Blood 2011, supplementary data (342.97 KB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, ym.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, ym.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
T
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, ym.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
V
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, ym.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, ym.. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A [Internet]. 1998;95(20):11709 - 14. http://view.ncbi.nlm.nih.gov/pubmed/9751730PDF icon Birgitta Olofsson et al., PNAS 1998 (470.59 KB)
Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, ym.. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A [Internet]. 1998;95(20):11709 - 14. http://view.ncbi.nlm.nih.gov/pubmed/9751730PDF icon Birgitta Olofsson et al., PNAS 1998 (470.59 KB)
Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, ym.. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646PDF icon Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB)PDF icon Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB)PDF icon Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, ym.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229PDF icon Marc Achen et al., PNAS 1998 (447.59 KB)
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, ym.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229PDF icon Marc Achen et al., PNAS 1998 (447.59 KB)
Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol [Internet]. 1998;177(3):439 - 52. http://view.ncbi.nlm.nih.gov/pubmed/9808152PDF icon Michael Pepper et al., Journal of Cellular Physiology 1998 (689.97 KB)
Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem [Internet]. 2006;281(17):12187 - 95. http://view.ncbi.nlm.nih.gov/pubmed/16505489PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB)
Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem [Internet]. 2006;281(17):12187 - 95. http://view.ncbi.nlm.nih.gov/pubmed/16505489PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, ym.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, ym.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)

Sivut